

REVENIO

Revenio Group Corporation: iCare and EyRIS into distribution collaboration in AI solutions for retinal screening

Revenio Group Corporation | Press Release | January 26, 2024 at 12:00:00 EET

iCare and Singapore-based EyRIS launch a partnership to distribute EyRIS 's Artificial Intelligence product SELENA+. iCare will now offer SELENA+ analysis in South-East Asia and Brazil for its iCare ILLUME retinal screening solution based on retinal images.

EyRIS is a leading and highly respected company specialising in artificial intelligence for medical image analysis. SELENA+ is already deployed in over 30 countries worldwide and is one of the pioneering AI solutions in National Diabetic Retinopathy Screening Programs.

The iCare ILLUME retinal screening solution uses AI-generated image analysis for diabetic retinopathy screening, age-related macular degeneration (AMD) and glaucoma. The iCare ILLUME solution supports clinical decision-making and is based on high-quality image data produced by iCare's retinal imaging devices and cloud-based software solutions. AI enables the efficient processing of large numbers of images, thereby improving screening accessibility. This holistic solution optimizes patient care pathways and the processes of eye care professionals.

"This is an exciting opportunity to contribute to keeping the wonderful world visible for all. Together with EyRIS, we are implementing a top-performance screening solution based on fundus images. We start by screening diabetic retinopathy from diabetics and bring to market an integrated service that is fast and easy to use thanks to automation. High-quality images from the iCare DRSplus fundus imaging system provide a good foundation for the solution", says Pirjo Kortteisto, Business Line Director of Icare Finland.

"Through this groundbreaking collaboration, we aim to showcase the efficiency and effectiveness of AI technology within a cutting-edge platform. Our collective efforts are focused on optimizing workflows and streamlining processes in eye care. The ultimate goal is to effectively prevent blindness and create a comprehensive patient journey from home care to primary care to tertiary care", says Steven Ang, Chief Strategy Officer at EyRIS.

For further information, please contact

Pirjo Kortteisto, Business Line Director

pirjo.kortteisto@revenio.fi

Distribution

Principal media

www.reveniogroup.fi

REVENIO

Revenio Group in brief

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and fundus imaging devices as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2022, the Group's net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

iCare in brief

iCare is a Finnish company that develops and manufactures innovative tonometers, retinal imaging devices and software solutions for the diagnosis and screening of eye diseases. iCare's vision is to keep the world visible to everyone, and its goal is to facilitate the identification and treatment of eye diseases through its technological solutions. iCare's products are reliable, efficient, and user-friendly, enabling accurate diagnoses to be made at an early stage. iCare collaborates with industry experts and is committed to continually developing new solutions to promote eye health. iCare is part of Helsinki Stock Exchange listed Revenio Group Corporation.

EyRIS in brief

EyRIS aims to transfigure the delivery of healthcare through AI-powered solutions, with the ultimate goal of being the game changer in the future of first-stage medical diagnostics. Its foray into the healthcare industry focuses on the development and commercialization of innovative products to revolutionize the detection of retinal and chronic diseases in our communities. Our flagship product, SELENA+, is an AI that is capable of detecting three retinal diseases, diabetic retinopathy, glaucoma suspect and age-related macular degeneration. SELENA+ has transcended significant geographical barriers by establishing its presence in more than 30 countries today and is currently deployed in population screening programs with three Ministry of Health in Asia and the Middle East.

For more information visit: <https://eyris.io/>

Contact: Steven Ang, Chief Strategy Officer, steven.ang@nova-hub.com

Attachments

[Revenio Group Corporation: iCare and EyRIS into distribution collaboration in AI solutions for retinal screening](#)